Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27715084 | 1.00 | NR1H4 (0.41) | NR1H4PDE4DGPR119EPHA2MAPT | |
| SCHEMBL1551905 | 0.87 | EPHA2 (0.46) | PDE4DEPHA2SMN1; SMN2ERBB2EPHB4 | |
| SCHEMBL1552545 | 0.83 | KDM1A (0.41) | NR1H4GPR119EPHA2MAPTSMN1; SMN2 | |
| SCHEMBL27695185 | 0.83 | KDM1A (0.41) | NR1H4GPR119EPHA2MAPTSMN1; SMN2 | |
| SCHEMBL5297895 | 0.82 | DRD4 (0.45) | NR1H4GPR119EPHA2ERBB2EPHB4 | |
| SCHEMBL4476703 | 0.82 | JAK2 (0.49) | GPR119EPHA2SMN1; SMN2USP30JAK2 | |
| SCHEMBL31076372 | 0.77 | MAPT (0.43) | NR1H4EPHA2MAPTSMN1; SMN2ERBB2 | |
| SCHEMBL1551955 | 0.77 | EPHA2 (0.47) | EPHA2MAPTERBB2EPHB4PDE4B | |
| SCHEMBL1551950 | 0.76 | USP2 (0.43) | GPR119EPHA2MAPTSMN1; SMN2ERBB2 | |
| SCHEMBL1551948 | 0.76 | USP2 (0.43) | GPR119EPHA2MAPTSMN1; SMN2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | NR1H4 251/4885PDE4D 521/4885GPR119 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.